anti-NY-ESO-1/HLA DR1 and HLA DP4 CD4 TCR T-cell therapy + anti-NY-ESO-1/HLA-A*0201 CD8 TCR T-cell therapy DEACT (Tactiva Therapeutics)

N/A

Report date: 2025/01/26 19:25:19

Base Information

Drug Nameanti-NY-ESO-1/HLA DR1 and HLA DP4 CD4 TCR T-cell therapy + anti-NY-ESO-1/HLA-A*0201 CD8 TCR T-cell therapy DEACT (Tactiva Therapeutics)
Drug Alias Nameanti-NY-ESO-1 TCR T-cell therapy DEACT platform (Tactiva Therapeutics)anti-NY-ESO-1/HLA DR1 and HLA DP4 CD4 TCR T-cell therapy + anti-NY-ESO-1/HLA-A*0201 CD8 TCR T-cell therapy DEACT (Tactiva Therapeutics)dual enhanced adoptive cell therapy DEACT (Tactiva Therapeutics)anti-NY-ESO-1/HLA DR1 and HLA DP4 CD4 TCR T-cell therapy + anti-NY-ESO-1/HLA A2.1 CD8 TCR T-cell therapy DEACT (Tactiva Therapeutics)
ClassificationBiologics > Protein drugs > Recombinant proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionHistocompatibility antigens class II modulatorsHLA Class I Histocompatibility Antigen, A-2 alpha Chain modulatorsCancer/testis antigen 1 modulators
TargetsHLA Class I Histocompatibility Antigen, A-2 alpha ChainCancer/testis antigen 1Histocompatibility antigens class II
Therapy Area/IndicationsSolid tumoursMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTactiva Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesTactiva Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A